What is Stem Pharm?
Stem Pharm is at the forefront of developing advanced synthetic biomaterials tailored for sophisticated in vitro cellular models and manufacturing processes. The company's core focus lies in creating human neural organoids, which are instrumental in disease modeling and drug discovery, particularly for neurodegenerative conditions. Their product portfolio includes physiologically relevant organoids equipped with microglia for neuroimmune drug discovery, alongside chemically-defined hydrogels and pre-coated cell culture plates. Stem Pharm's innovative solutions are designed to accelerate neurologic disease modeling, facilitate target discovery, enable phenotypic drug screening, and support neurotoxicity assessments, thereby empowering clients to generate critical insights and bolster confidence in their drug development pipelines.
How much funding has Stem Pharm raised?
Stem Pharm has raised a total of $73K across 1 funding round:
Debt
$73K
Debt (2021): $73K with participation from PPP
Key Investors in Stem Pharm
PPP
Public-Private Partnership
What's next for Stem Pharm?
With the recent influx of expansion capital, Stem Pharm is poised for significant growth and innovation. The company's strategic direction will likely involve scaling its manufacturing capabilities, further enhancing its organoid technology, and expanding its research and development efforts. This investment will also enable Stem Pharm to forge deeper partnerships within the pharmaceutical and biotechnology industries, solidifying its position as a key player in the development of next-generation cellular models for drug discovery and therapeutic development. The company's trajectory suggests a continued focus on addressing unmet needs in neurobiology and regenerative medicine.
See full Stem Pharm company page
